Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
February 9, 2021updated 21 Oct 2021 11:30am

Coronavirus company news summary – China approves SinoVac’s Covid-19 vaccine for over 18s – CanSino’s Covid-19 vaccine was 65.7% effective in clinical trials

By Allie Nawrat

9 February 2021 

Chinese Sinovac Biotech announced that it has been granted a conditional marketing authorisation by the China National Medical Products Administration (NMPA) for CoronaVac, the company’s Covid-19 vaccine, for individuals aged over 18. The approval was granted on the basis of results from the company’s Phase III clinical trials, the efficacy and safety of which is yet to be confirmed.

Veru published positive data regarding a cancer drug’s potential in fighting the Covid-19 disease. The prostate cancer treatment achieved positive efficacy and safety data in the company’s Phase II clinical trial in hospitalised patients suffering from acute respiratory distress syndrome caused by Covid-19.

Reuters reports that Pakistan’s health minister confirmed that Chinese CanSino Biologics’ Covid-19 vaccine achieved 65.7% efficacy in preventing symptomatic cases in clinical trials. The vaccine also showed a 90.98% success rate in stopping severe disease in one of its interim analysis of global trials being carried out in Pakistan, Mexico, Russia, Argentina and Chile.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU